Chromogranin C Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-42511
Key Product Details
Species Reactivity
Validated:
Human
Predicted:
Canine (100%), Porcine (100%). Backed by our 100% Guarantee.
Applications
Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence C-QELGKLTGPNNQKRE corresponding to internal region according to NP_003460.2.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Chromogranin C Antibody
Western Blot: Chromogranin C Antibody [NBP2-42511]
Western Blot: Chromogranin C Antibody [NBP2-42511] - Analysis of Human Cerebellum lysate (35 ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.Applications for Chromogranin C Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:128000
Western Blot
0.3 - 1 ug/ml
Application Notes
WB: Approx. 70 kDa band observed in human brain (cerebellum) lysates (calculated MW of 70.9 kDa band according to NP_003460.2).
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Chromogranin C
Alternate Names
CHCG, Chromogranin-C, EM66, SCG2, secretogranin IICHGCchromogranin-C, secretoneurin, SgIIsecretogranin-2, SN
Entrez Gene IDs
7857 (Human)
Gene Symbol
SCG2
Additional Chromogranin C Products
Product Documents for Chromogranin C Antibody
Product Specific Notices for Chromogranin C Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...